(PO11-17-22) Equivalent Glycemic Load (EGL) of Atkins Chocolate Peanut Butter Bar and Atkins Chocolate Ready-to-Drink Shake in People With Type 2 Diabetes

The ePoster content is available to NUTRITION 2022 LIVE ONLINE attendees who are logged in.<br><br>If you are registered, log in and then come back here to use this button.

Presenting Author(s)

TW

Thomas MS Wolever, MD PhD
– Medical Director and Principal Scientist, INQUIS Clinical Research, Ltd., Toronto, Ontario, Canada

Co-Author(s)

Alexandra L. Jenkins, PhD RD
– Senior Scientist, INQUIS Clinical Research, Toronto, Ontario, Canada
JC

Jonathan Clinthorne, PhD
– Simply Good Foods USA, Inc.
CH

Colette Heimowitz, MSc
– Simply Good Foods USA, Inc.

Disclosure(s):

Thomas MS Wolever, MD PhD: INQUIS Clinical Research: Employee (Ongoing)

Alexandra L. Jenkins, PhD RD: Anderson Advanced Ingredients: Independent Contractor (including contracted research) (Ongoing)
Nutrisystem: Independent Contractor (including contracted research) (Ongoing)

Objectives: It is difficult to estimate the glycemic impact of low-carbohydrate (low-CHO) foods from the information in the Nutrition Facts Table. We developed equivalent glycemic load (EGL) to quantify the glycemic impact of low-CHO foods in people without diabetes. The current objective was to determine the feasibility and safety of measuring EGL in people with type 2 diabetes (T2D).

Methods: Overnight fasted adults with T2D treated by diet or oral agents and A1c < 8.1% consumed 1 serving of Atkins Chocolate Peanut Butter Bar (CPB) or Atkins Milk Chocolate Shake (MCS) or 45g white bread (WB) in random order on 3 separate days. CPB/MCS, respectively, contained 150/160 kcal, 14/9g fat, 16/15g protein, 23/5g CHO and 12/3g fiber. We took finger-stick blood fasting and every 30min for 3h after starting to eat. Serum glucose was measured by glucometer (analytic CV=8.6%) and by the Vitros Chemistry System (Vitros, CV=1.6%). In each subject F/(WB/Cwb) was calculated where F = incremental area under the curve (iAUC) for the food, WB = iAUC after WB and Cwb = 20.8 (the amount of CHO in WB). EGL = mean F/(WB/Cwb), after excluding values >2SD from the mean.

Results: We screened 18 subjects; 4 were ineligible (A1c >8.0%), 14 were enrolled and 2 dropped out. The remaining 12 subjects (5 males, 7 females; aged 43-75 (mean±SD, 63±11) yr; BMI 23.0-56.0 (35.2±9.0) kg/m²) completed in the study. By Vitros, the EGLs (mean [95% confidence interval] for CPB, 4.1 [2.0, 6.2] g (n=11), and MCD, 3.8 [1.6, 6.0] g (n=11) were similar to those by glucometer CPB, 5.8 [2.5, 9.1] g (n=12) and MCD, 3.0 [0.8, 5.2] g (n=11). There were no episodes of hypoglycemia during the study. Loose stools were experienced by 1 subject after CPB and by a different subject after MCS, events considered to be possibly related to the study products.

Conclusions: The results suggest it is feasible and safe to measure EGL in people with T2D not taking insulin.

Funding Sources: Simply Good Foods USA, Inc.